This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Alexander, M.S. Articles by Lockett, C.M. Search for Related Content PubMed Articles by Alexander, M.S. Articles by Lockett, C.M. Social Bookmarking                         What's this?

Once-daily controlled release remoxipride is equieffective with twice-daily immediate release remoxipride in the treatment of schizophrenia

Department of Psychiatry, St. James's University Hospital, Leeds LS9 7TF

S.K. Chakravarti

7 Hungerford Road, Huddersfield HD3 3AL

K. Sundararajan

Department of Psychiatry, The General Hospital, Halifax HX3 OPW

J.M. Mullin

Department of General Psychiatry and Psychogeriatrics, De La Pole Hospital, Willerby, Hull HU10 6ED

S.H. Shaw

Department of Psychiatry, Stanley Royd Hospital, Wakefield WF14 4DQ, UK

M. Blomqvist

Astra Arcus AB, S-15185 Södertälje, Sweden

C.M. Lockett

Department of Clinical Research, Astra Pharmaceuticals Ltd., Kings Langley WD4 8DH, UK

A controlled release (CR) formulation of remoxipride (Roxiam^®, Astra) given once-daily was compared to immediate release (IR) remoxipride given twice-daily, with respect to efficacy and tolerability, in a 4-week multicentre parallel-group dose titration (200-600 mg/day) study with acutely ill schizophrenic patients. Forty- three patients received remoxipride CR (mean dose 344 mg/day) and 49 patients received remoxipride IR (mean dose 346 mg/day). Efficacy was assessed using the Kolakowska version of the Brief Psychiatric Rating Scale (BPRS score of 18 points at entry) and the Clinical Global Impression scale (CGI), while extrapyramidal symptoms were rated using the Simpson and Angus scale. Both formulations of remoxipride produced clinical improvement, with the BPRS median total score falling from 35 at baseline to 16 at last rating in the remoxipride CR group, and from 33 to 12.5 in the remoxipride IR group. More than 70% of the patients in both groups were assessed as 'much improved' or 'very much improved' according to the CGI scale. Both formulations of remoxipride were well-tolerated, with a low incidence of treatment-emergent adverse symptoms, including extrapyramidal side effects. No statistically significant differences were detected between the treatment groups with regard to efficacy, safety or tolerability.

Key Words: remoxipride • schizophrenia • controlled release • antipsychotic • once-daily

Journal of Psychopharmacology, Vol. 7, No. 3, 276-282 (1993)
DOI: 10.1177/026988119300700307


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?